Cisapride and Fatal Arrhythmia

Diane K. Wysowski; Janos T Bacsanyi

doi:10.1056/nejm199607253350416

July 25, 1996New England Journal of MedicineOpen Access

Cisapride and Fatal Arrhythmia

View Full Paper

Ask AI

Bookmark

Share

Why the study?

Is cisapride associated with fatal arrhythmias?

Key Points

To assess spontaneous postmarketing reports of fatal and life-threatening cardiac arrhythmias occurring in patients prescribed cisapride.
Reviewed adverse event reports submitted to the United States Food and Drug Administration's MedWatch surveillance system between September 1993 and April 1996.
Documented postmarketing reports associating cisapride with severe and fatal cardiac arrhythmias following its commercial introduction.

Structured PICO

Is cisapride associated with fatal arrhythmias?

P

Population

Patients reported to the Food and Drug Administration's MedWatch system from September 1993 to April 1996

I

Intervention

Cisapride

O

Outcome

Fatal arrhythmiasafety

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Early post-marketing surveillance data from the FDA MedWatch system highlighted a risk of fatal arrhythmias associated with cisapride.

Abstract

To the Editor: From September 1993, the month in which the marketing of cisapride (Propulsid, Janssen Pharmaceutica, Titusville, N.J.) began, to April 1996, the Food and Drug Administration's MedWa...

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wysowski et al. (1996) studied this question.

synapsesocial.com/papers/6a753a5e9c92392688b20b04 https://doi.org/10.1056/nejm199607253350416

View Full Paper

Ask AI

Bookmark

Share

Cisapride and Fatal Arrhythmia

Key Points

Structured PICO

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Cisapride and Fatal Arrhythmia

Key Points

Structured PICO

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading